uniQure N.V. (QURE)
Develops gene therapies to treat rare genetic diseases like hemophilia and Huntington's.
$36.66-0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+167.7%
The outlook
QURE is trading near the middle of its 52-week range with strong analyst backing—11 analysts rate it a Strong Buy on average. The stock sits above both its 50- and 200-day moving averages, signaling upward momentum in recent weeks. The average analyst price target sits roughly 76% above the current price.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 11 analysts
Price trendAbove its 50- & 200-day averages
52-week range44% of the way from its 52-week low to high
Price targetAvg target +76% vs current price
Analyst price target
~12-month · 11 analysts$64.62average target+76.3% vs now
Now $36.66
Low $35.87High $92.49
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.52B
52-wk high
$71.50
52-wk low
$8.73
50-day avg
$35.55
200-day avg
$28.96
Trailing P/E
—